PNC Financial Services Group Inc. Has $2.51 Million Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

PNC Financial Services Group Inc. trimmed its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNYFree Report) by 16.3% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 13,118 shares of the biopharmaceutical company’s stock after selling 2,547 shares during the period. PNC Financial Services Group Inc.’s holdings in Alnylam Pharmaceuticals were worth $2,511,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Norges Bank bought a new position in shares of Alnylam Pharmaceuticals during the fourth quarter valued at $390,438,000. Wellington Management Group LLP boosted its holdings in Alnylam Pharmaceuticals by 6.0% during the 3rd quarter. Wellington Management Group LLP now owns 6,431,814 shares of the biopharmaceutical company’s stock worth $1,139,074,000 after acquiring an additional 364,021 shares during the last quarter. abrdn plc grew its position in Alnylam Pharmaceuticals by 910.7% in the 4th quarter. abrdn plc now owns 232,716 shares of the biopharmaceutical company’s stock worth $44,544,000 after purchasing an additional 209,691 shares in the last quarter. Royal London Asset Management Ltd. lifted its holdings in Alnylam Pharmaceuticals by 86.7% during the third quarter. Royal London Asset Management Ltd. now owns 306,595 shares of the biopharmaceutical company’s stock worth $54,303,000 after acquiring an additional 142,357 shares during the period. Finally, Federated Hermes Inc. bought a new position in shares of Alnylam Pharmaceuticals during the 4th quarter valued at approximately $26,250,000. 92.97% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

ALNY has been the subject of a number of recent research reports. HC Wainwright lifted their price objective on shares of Alnylam Pharmaceuticals from $395.00 to $400.00 and gave the company a “buy” rating in a research note on Tuesday, May 7th. Wolfe Research began coverage on Alnylam Pharmaceuticals in a research report on Thursday, February 15th. They set a “peer perform” rating on the stock. Citigroup reduced their target price on shares of Alnylam Pharmaceuticals from $237.00 to $227.00 and set a “buy” rating on the stock in a report on Friday, February 16th. Needham & Company LLC reiterated a “buy” rating and issued a $200.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Thursday, May 2nd. Finally, Chardan Capital reissued a “buy” rating and issued a $225.00 target price on shares of Alnylam Pharmaceuticals in a research note on Friday, May 3rd. Seven equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $216.19.

View Our Latest Analysis on ALNY

Alnylam Pharmaceuticals Price Performance

ALNY stock opened at $147.76 on Monday. The business has a 50 day simple moving average of $149.37 and a 200-day simple moving average of $164.03. The firm has a market capitalization of $18.69 billion, a PE ratio of -55.13 and a beta of 0.41. Alnylam Pharmaceuticals, Inc. has a 1 year low of $141.98 and a 1 year high of $218.88.

Alnylam Pharmaceuticals (NASDAQ:ALNYGet Free Report) last released its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) EPS for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.23. The firm had revenue of $494.33 million for the quarter, compared to analyst estimates of $428.01 million. The firm’s revenue for the quarter was up 54.8% on a year-over-year basis. During the same quarter last year, the company earned ($1.40) earnings per share. On average, equities research analysts expect that Alnylam Pharmaceuticals, Inc. will post -3.77 EPS for the current year.

Alnylam Pharmaceuticals Company Profile

(Free Report)

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

Read More

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNYFree Report).

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.